Nothing Special   ยป   [go: up one dir, main page]

CA2772964C - Procede de preparation de proteines derivees de plantes - Google Patents

Procede de preparation de proteines derivees de plantes Download PDF

Info

Publication number
CA2772964C
CA2772964C CA2772964A CA2772964A CA2772964C CA 2772964 C CA2772964 C CA 2772964C CA 2772964 A CA2772964 A CA 2772964A CA 2772964 A CA2772964 A CA 2772964A CA 2772964 C CA2772964 C CA 2772964C
Authority
CA
Canada
Prior art keywords
plant
proteins
protein
suprastructure
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2772964A
Other languages
English (en)
Other versions
CA2772964A1 (fr
Inventor
Louis-Philippe Vezina
Manon Couture
Dany Paquet
Michele Dargis
Marc-Andre D'aoust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicago Inc
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of CA2772964A1 publication Critical patent/CA2772964A1/fr
Application granted granted Critical
Publication of CA2772964C publication Critical patent/CA2772964C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Kโ€”PEPTIDES
    • C07K14/00โ€”Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415โ€”Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Kโ€”PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00โ€”Medicinal preparations containing antigens or antibodies
    • A61K39/12โ€”Viral antigens
    • A61K39/145โ€”Orthomyxoviridae, e.g. influenza virus
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Kโ€”PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00โ€”Medicinal preparations containing antigens or antibodies
    • A61K39/12โ€”Viral antigens
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00โ€”Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00โ€”Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12โ€”Antivirals
    • A61P31/14โ€”Antivirals for RNA viruses
    • A61P31/16โ€”Antivirals for RNA viruses for influenza or rhinoviruses
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00โ€”Drugs for immunological or allergic disorders
    • A61P37/02โ€”Immunomodulators
    • A61P37/04โ€”Immunostimulants
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Kโ€”PEPTIDES
    • C07K1/00โ€”General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14โ€”Extraction; Separation; Purification
    • C07K1/34โ€”Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00โ€”Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09โ€”Recombinant DNA-technology
    • C12N15/63โ€”Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79โ€”Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82โ€”Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201โ€”Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202โ€”Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8203โ€”Virus mediated transformation
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00โ€”Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09โ€”Recombinant DNA-technology
    • C12N15/63โ€”Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79โ€”Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82โ€”Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241โ€”Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242โ€”Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257โ€”Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00โ€”Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09โ€”Recombinant DNA-technology
    • C12N15/63โ€”Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79โ€”Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82โ€”Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241โ€”Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242โ€”Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257โ€”Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258โ€”Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00โ€”Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00โ€”Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02โ€”Recovery or purification
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Kโ€”PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00โ€”Medicinal preparations containing antigens or antibodies
    • A61K2039/51โ€”Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517โ€”Plant cells
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Kโ€”PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00โ€”Medicinal preparations containing antigens or antibodies
    • A61K2039/51โ€”Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525โ€”Virus
    • A61K2039/5258โ€”Virus-like particles
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00โ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011โ€”Details
    • C12N2760/16011โ€”Orthomyxoviridae
    • C12N2760/16111โ€”Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123โ€”Virus like particles [VLP]
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00โ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011โ€”Details
    • C12N2760/16011โ€”Orthomyxoviridae
    • C12N2760/16111โ€”Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134โ€”Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Cโ€”CHEMISTRY; METALLURGY
    • C12โ€”BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Nโ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00โ€”MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011โ€”Details
    • C12N2760/16011โ€”Orthomyxoviridae
    • C12N2760/16111โ€”Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151โ€”Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)

Abstract

L'invention concerne des procรฉdรฉs de prรฉparation de protรฉines ou protรฉines ร  suprastructure dรฉrivรฉes de plantes. Le procรฉdรฉ peut comprendre l'obtention d'une plante ou d'une matiรจre vรฉgรฉtale comprenant des protรฉines ou protรฉines ร  suprastructure localisรฉes dans l'apoplaste, la production d'une fraction protoplaste/sphรฉroplaste et d'une fraction apoplaste ร  partir de la plante ou de la matiรจre vรฉgรฉtale, et la rรฉcupรฉration de la fraction apoplaste. La fraction apoplaste comprend les protรฉines ou protรฉines ร  suprastructure dรฉrivรฉes de plantes. En variante, les protรฉines ou protรฉines ร  suprastructure peuvent รชtre obtenues ร  partir d'une plante ou d'une matiรจre vรฉgรฉtale comprenant des protรฉines ou protรฉines ร  suprastructure dรฉrivรฉes de plantes par digestion de la matiรจre vรฉgรฉtale en utilisant une composition enzymatique de dรฉgradation des parois cellulaires pour produire une fraction digรฉrรฉe. La fraction digรฉrรฉe est filtrรฉe pour produire une fraction filtrรฉe, et les protรฉines ou protรฉines ร  suprastructure dรฉrivรฉes de plantes sont rรฉcupรฉrรฉes ร  partir de la fraction filtrรฉe.
CA2772964A 2009-09-22 2010-09-21 Procede de preparation de proteines derivees de plantes Active CA2772964C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24478609P 2009-09-22 2009-09-22
US61/244,786 2009-09-22
PCT/CA2010/001489 WO2011035423A1 (fr) 2009-09-22 2010-09-21 Procรฉdรฉ de prรฉparation de protรฉines dรฉrivรฉes de plantes

Publications (2)

Publication Number Publication Date
CA2772964A1 CA2772964A1 (fr) 2011-03-31
CA2772964C true CA2772964C (fr) 2020-10-27

Family

ID=43795254

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2772962A Active CA2772962C (fr) 2009-09-22 2010-09-21 Procede de preparation de vlp derivees de plantes
CA2772964A Active CA2772964C (fr) 2009-09-22 2010-09-21 Procede de preparation de proteines derivees de plantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2772962A Active CA2772962C (fr) 2009-09-22 2010-09-21 Procede de preparation de vlp derivees de plantes

Country Status (27)

Country Link
US (2) US11826419B2 (fr)
EP (3) EP3354657B1 (fr)
JP (2) JP5554414B2 (fr)
KR (4) KR20180026562A (fr)
CN (4) CN107129973A (fr)
AR (2) AR078432A1 (fr)
AU (2) AU2010300033B2 (fr)
BR (2) BR112012006415B1 (fr)
CA (2) CA2772962C (fr)
DK (3) DK2480658T3 (fr)
ES (3) ES2642631T3 (fr)
HR (3) HRP20220478T1 (fr)
HU (3) HUE036776T2 (fr)
IL (4) IL218393A0 (fr)
IN (2) IN2012DN02637A (fr)
MX (2) MX2012003373A (fr)
MY (2) MY158475A (fr)
NO (2) NO2480658T3 (fr)
NZ (2) NZ598508A (fr)
PL (3) PL2480560T3 (fr)
PT (3) PT3354657T (fr)
RU (2) RU2567012C2 (fr)
SG (2) SG178947A1 (fr)
SI (3) SI2480560T1 (fr)
TR (1) TR201803560T4 (fr)
WO (2) WO2011035423A1 (fr)
ZA (2) ZA201202835B (fr)

Families Citing this family (34)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (fr) 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
EP2238253B1 (fr) 2007-11-27 2012-09-12 Medicago Inc. Particules pseudovirales (vlp) de la grippe recombinรฉes produites dans des plantes transgรฉniques exprimant l'hรฉmagglutinine
IN2012DN00650A (fr) 2009-06-24 2015-06-12 Medicago Inc
NO2480658T3 (fr) * 2009-09-22 2018-02-03
TWI526539B (zh) 2010-12-22 2016-03-21 ่‹œ่“ฟ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆค็‰ฉไธญ็”Ÿ็”ข้กž็—…ๆฏ’้ก†็ฒ’(vlp)็š„ๆ–นๆณ•ๅŠไปฅ่ฉฒๆ–นๆณ•็”Ÿ็”ขไน‹vlp
TWI620816B (zh) 2011-03-23 2018-04-11 ่‹œ่“ฟ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆค็‰ฉ่ก็”Ÿ่›‹็™ฝๅ›žๆ”ถๆ–นๆณ•
WO2012171104A1 (fr) 2011-06-13 2012-12-20 Medicago Inc. Production de particules de type virus de la rage dans des plantes
WO2013044203A2 (fr) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Nouveaux vaccins ร  base de protรฉine hรฉmagglutinine de la grippe
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
PL2760882T3 (pl) 2011-09-30 2023-09-11 Medicago Inc. Zwiฤ™kszenie wydajnoล›ci czฤ…steczek wirusowopodobnych w roล›linach
CN104114696B (zh) * 2011-12-21 2017-05-03 ้˜ฟๆ™ฎๆ–ฏๆœ‰้™่ดฃไปปๅ…ฌๅธ ไฝฟ็”จๅ…ทๆœ‰ๅฏนๆฐด่งฃ้…ถๆŠ—ๆ€ง็š„่กฃๅฃณ็š„vlp็š„ๆ–นๆณ•
JP6406655B2 (ja) * 2012-02-22 2018-10-17 ไธ‰่ฑๅ•†ไบ‹ใƒ•ใƒผใƒ‰ใƒ†ใƒƒใ‚ฏๆ ชๅผไผš็คพ ๆค็‰ฉๆ€ง้ฃŸๅ“็ด ๆใฎ่ปŸๅŒ–ๆ–นๆณ•ใ€่ปŸๅŒ–่ฃฝๅ‰คใ€่ปŸๅŒ–ใ—ใŸๆค็‰ฉๆ€ง้ฃŸๅ“็ด ๆใŠใ‚ˆใณใใ‚Œใ‚’็”จใ„ใŸ้ฃŸๅ“
CA2864733C (fr) * 2012-03-22 2018-09-18 Fraunhofer Usa, Inc. Particules de type virus comprenant une matrice de proteine a partir d'un virus enveloppe de plante et utilisations de celles-ci
AU2013312971B2 (en) 2012-09-05 2019-04-18 Medicago Inc. Picornavirus-like particle production in plants
US9617297B2 (en) * 2012-10-11 2017-04-11 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
CA2907591A1 (fr) * 2013-03-28 2014-10-02 Medicago Inc. Production de particules de type viral de la grippe dans des plantes
WO2015034042A1 (fr) 2013-09-06 2015-03-12 ไธ‰่ฑๅŒ–ๅญฆๆ ชๅผไผš็คพ Procรฉdรฉ de production d'une protรฉine ร  l'aide d'une plante
WO2015054639A1 (fr) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins contre le virus d'epstein-barr
CA2936350C (fr) 2014-01-10 2023-01-31 Medicago Inc. Elements activateurs du cpmv
RU2731295C2 (ru) 2014-07-11 2020-09-01 ะœะตะดะธะบะฐะณะพ ะ˜ะฝะบ. ะœะพะดะธั„ะธะบะฐั†ะธั ะฟั€ะพะดัƒั†ะธั€ะพะฒะฐะฝะธั ะฑะตะปะบะพะฒ ะฒ ั€ะฐัั‚ะตะฝะธัั…
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
JP2019129705A (ja) * 2016-03-31 2019-08-08 ๆ—ฅๆœฌใŸใฐใ“็”ฃๆฅญๆ ชๅผไผš็คพ ๆค็‰ฉใซ็‰ฉ่ณชใ‚’ๅฐŽๅ…ฅใ™ใ‚‹ๆ–นๆณ•
IL303650B1 (en) 2016-09-02 2024-10-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
WO2019104439A1 (fr) 2017-11-30 2019-06-06 Medicago Inc. Protรฉines vp1 de norovirus modifiรฉes et protรฉines vp1 de norovirus comprenant des vlp
TW202016308A (zh) 2018-06-27 2020-05-01 ๅŠ ๆ‹ฟๅคงๅ•†่‹œ่“ฟ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆตๆ„Ÿ็—…ๆฏ’่ก€็ƒๅ‡้›†็ด ็ช่ฎŠ้ซ”
JP7429684B6 (ja) * 2018-07-13 2024-03-15 ใƒกใƒ‡ใ‚ฃใ‚ซใ‚ด ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๆ”นๅค‰ใƒŽใƒญใ‚ฆใ‚คใƒซใ‚น๏ฝ–๏ฝ๏ผ‘ใ‚ฟใƒณใƒ‘ใ‚ฏ่ณชใŠใ‚ˆใณๆ”นๅค‰ใƒŽใƒญใ‚ฆใ‚คใƒซใ‚น๏ฝ–๏ฝ๏ผ‘ใ‚ฟใƒณใƒ‘ใ‚ฏ่ณชใ‚’ๅซใ‚€๏ฝ–๏ฝŒ๏ฝ
CN109112093B (zh) * 2018-09-05 2021-11-09 ไธŠๆตทไบค้€šๅคงๅญฆ ไธ€็ง้’่’ฟๅŽŸ็”Ÿ่ดจไฝ“้ซ˜ๆ•ˆๅˆ†็ฆปๅŠ็žฌๆ—ถ่ฝฌๅŒ–็š„ๆ–นๆณ•
CA3137447A1 (fr) * 2019-04-25 2020-10-29 Flagship Pioneering Innovations Vi, Llc Compositions et procedes se rapportant a des paquets de messagers vegetaux
CN110483616B (zh) * 2019-07-31 2021-06-04 ไธญๅ›ฝๅ†œไธš็ง‘ๅญฆ้™ขๅ†œไบงๅ“ๅŠ ๅทฅ็ ”็ฉถๆ‰€ ไปŽๆ„ŸๆŸ“็—…ๅŽŸ่Œ็š„ๆค็‰ฉ็ป„็ป‡ไธญๅˆ†็ฆป็—…ๅŽŸ่Œๅˆ†ๆณŒ็š„่ดจๅค–ไฝ“ๆ•ˆๅบ”่›‹็™ฝ็š„ๆ–นๆณ•
CN111060696B (zh) * 2019-12-27 2023-09-08 ๆน–ๅ—ๅ†œไธšๅคงๅญฆ ไธ€็ง้™ไฝŽๆค็‰ฉๅฐๅˆ†ๅญไฟกๅท่‚ฝๅ‡้˜ณๆ€ง็Ž‡็š„ๆ–นๆณ•
CN111718394A (zh) * 2020-06-28 2020-09-29 ๅนฟ่ฅฟๅฃฎๆ—่‡ชๆฒปๅŒบๅ†œไธš็ง‘ๅญฆ้™ข ไธ€็งๅŸบไบŽbppๆณ•็š„็”˜่”—็ป„็ป‡ๅ˜ๆ€ง่›‹็™ฝๆๅ–ๆ–นๆณ•
CN111826394A (zh) * 2020-08-07 2020-10-27 ๆต™ๆฑŸๅŽ็ผ”่ฏไธš้›†ๅ›ขๅŒป่ฏๅผ€ๅ‘ๆœ‰้™ๅ…ฌๅธ ๆค็‰ฉ็žฌๆ—ถ่กจ่พพ่ฝฝไฝ“็š„ๆž„ๅปบๅŠๅบ”็”จ
WO2022260849A1 (fr) 2021-06-09 2022-12-15 Nant Holdings Ip, Llc Procรฉdรฉs et systรจmes de production d'une protรฉine d'intรฉrรชt dans une plante
CN114934007B (zh) * 2022-07-01 2023-11-24 ๅนฟไธœ็œๅ†œไธš็ง‘ๅญฆ้™ขไฝœ็‰ฉ็ ”็ฉถๆ‰€ ไธ€็ง็”˜่–ฏๅŽŸ็”Ÿ่ดจไฝ“็š„ๅˆถๅค‡ๆ–นๆณ•

Family Cites Families (77)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPS62501263A (ja) 1984-11-29 1987-05-21 ใ‚นใ‚ฏใƒชใƒ„ใƒ—ใ‚นใ€€ใ‚ฏใƒชใƒ‹ใƒ„ใ‚ฏใ€€ใ‚ขใƒณใƒ‰ใ€€ใƒชใ‚ตโˆ’ใƒใ€€ใƒ•ใ‚ขใ‚ฆใƒณใƒ‡โˆ’ใ‚ทใƒจใƒณ ่„ฑใ‚ฐใƒชใ‚ณใ‚ทใƒซๅŒ–ใ‚ฆใ‚คใƒซใ‚น็ณ–ใ‚ฟใƒณใƒ‘ใ‚ฏ่ณชใซ้–ข้€ฃใ™ใ‚‹ใƒใƒชใƒšใƒ—ใƒใƒ‰้กžใŠใ‚ˆใณๆŠ—ไฝ“
JPS61265086A (ja) * 1985-05-21 1986-11-22 Mitsui Toatsu Chem Inc ใƒ—ใƒญใƒˆใƒ—ใƒฉใ‚นใƒˆใฎๅŸน้คŠๆณ•
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
ATE142883T1 (de) 1991-03-28 1996-10-15 Rooperol Na Nv Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren
UA48104C2 (uk) 1991-10-04 2002-08-15 ะะพะฒะฐั€ั‚ั–ั ะะณ ะคั€ะฐะณะผะตะฝั‚ ะดะฝะบ, ัะบะธะน ะผั–ัั‚ะธั‚ัŒ ะฟะพัะปั–ะดะพะฒะฝั–ัั‚ัŒ,ั‰ะพ ะบะพะดัƒั” ั–ะฝัะตะบั‚ะธั†ะธะดะฝะธะน ะฟั€ะพั‚ะตั—ะฝ, ะพะฟั‚ะธะผั–ะทะพะฒะฐะฝัƒ ะดะปั ะบัƒะบัƒั€ัƒะดะทะธ,ั„ั€ะฐะณะผะตะฝั‚ ะดะฝะบ, ัะบะธะน ะทะฐะฑะตะทะฟะตั‡ัƒั” ะฝะฐะฟั€ะฐะฒะปะตะฝัƒ ะฑะฐะถะฐะฝัƒ ะดะปั ัะตั€ั†ะตะฒะธะฝะธ ัั‚ะตะฑะปะฐ ะตะบัะฟั€ะตัั–ัŽ ะทะฒ'ัะทะฐะฝะพะณะพ ะท ะฝะตัŽ ัั‚ั€ัƒะบั‚ัƒั€ะฝะพะณะพ ะณะตะฝะฐ ะฒ ั€ะพัะปะธะฝั–, ั„ั€ะฐะณะผะตะฝั‚ ะดะฝะบ, ัะบะธะน ะทะฐะฑะตะทะฟะตั‡ัƒั” ัะฟะตั†ะธั„ั–ั‡ะฝัƒ ะดะปั ะฟะธะปะบัƒ ะตะบัะฟั€ะตัั–ัŽ ะทะฒ`ัะทะฐะฝะพะณะพ ะท ะฝะตัŽ ัั‚ั€ัƒะบั‚ัƒั€ะฝะพะณะพ ะณะตะฝะฐ ะฒ ั€ะพัะปะธะฝั–, ั€ะตะบะพะผะฑั–ะฝะฐะฝั‚ะฝะฐ ะผะพะปะตะบัƒะปะฐ ะดะฝะบ, ัะฟะพัั–ะฑ ะพะดะตั€ะถะฐะฝะฝั ะพะฟั‚ะธะผั–ะทะพะฒะฐะฝะพั— ะดะปั ะบัƒะบัƒั€ัƒะดะทะธ ะบะพะดัƒัŽั‡ะพั— ะฟะพัะปั–ะดะพะฒะฝะพัั‚ั– ั–ะฝัะตะบั‚ะธั†ะธะดะฝะพะณะพ ะฟั€ะพั‚ะตั—ะฝัƒ, ัะฟะพัั–ะฑ ะทะฐั…ะธัั‚ัƒ ั€ะพัะปะธะฝ ะบัƒะบัƒั€ัƒะดะทะธ ั‰ะพะฝะฐะนะผะตะฝัˆะต ะฒั–ะด ะพะดะฝั–ั”ั— ะบะพะผะฐั…ะธ-ัˆะบั–ะดะฝะธะบะฐ
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
AU6504796A (en) * 1995-07-20 1997-02-18 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US5773695A (en) * 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
NZ510358A (en) * 1998-08-11 2002-09-27 Large Scale Biology Corp Method for recovering proteins from the interstitial fluid of plant tissues
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
WO2000037663A2 (fr) 1998-12-23 2000-06-29 The Samuel Roberts Noble Foundation, Inc. Procede de transformation de vegetaux
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
EP1171618A2 (fr) 1999-04-21 2002-01-16 The Samuel Roberts Noble Foundation Procede de transformation de plante
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2002012454A1 (fr) * 2000-08-08 2002-02-14 The Kitasato Institute Micrograins de type viral et procede de production correspondant
DK1362109T3 (da) 2001-01-18 2009-07-27 Vlaams Interuniv Inst Biotech Rekombinante oligomere protein-komplekser med forรถget immunogent potentiale
AU2002324973A1 (en) 2001-09-14 2003-04-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandandten Forschung E.V. Immunoglobulin having particular framework scaffold and methods of making and using
EP1572910B1 (fr) 2002-02-13 2015-12-02 Wisconsin Alumni Research Foundation Signal d'incorporation de vecteurs de virus de la grippe
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
NZ546945A (en) 2002-03-19 2008-04-30 Plant Res Int Bv A plant host cell system for the expression of human GnTIII
KR20060035596A (ko) * 2003-05-05 2006-04-26 ๋ณด์ด์Šค ํ†ฐ์Šจ ์ธ์Šคํ„ฐํŠœํŠธ ํฌ ํ”Œ๋žœํŠธ ๋ฆฌ์„œ์น˜ ์™ธ๋ž˜์œ ์ „์ž๋„์ž… ์‹๋ฌผ๋กœ๋ถ€ํ„ฐ ์œ ๋ž˜๋œ ๋ฉด์—ญ๋ณดํ˜ธ์„ฑ ์กฐ์„ฑ๋ฌผ์„์ œ์กฐํ•˜๊ธฐ ์œ„ํ•œ ๋ฒกํ„ฐ์™€ ์„ธํฌ
US20040268442A1 (en) 2003-05-05 2004-12-30 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CN1560227A (zh) * 2004-02-25 2005-01-05 ็ฆๅปบๅธˆ่Œƒๅคงๅญฆ ้›จ็”Ÿ็บข็ƒ่—ปๅŽŸ็”Ÿ่ดจไฝ“ๅˆถๅค‡ไธŽๅ†็”ŸๆŠ€ๆœฏ
WO2006016380A2 (fr) 2004-08-13 2006-02-16 Council Of Scientific And Industrial Research Vaccin contre la rage a base de proteine g chimerique
US9155483B2 (en) 2004-12-03 2015-10-13 The Invention Science Fund I, Llc Vision modification with reflected image
EP1861506B1 (fr) * 2005-03-15 2015-04-15 BP Corporation North America Inc. Cellulases, acides nucleiques codant pour ces cellulases, et procedes de production et d'utilisation de ces cellulases
PL2374892T3 (pl) 2005-04-29 2018-06-29 University Of Cape Town Ekspresja biaล‚ek wirusa w roล›linach
CN100410378C (zh) 2005-05-09 2008-08-13 ไธญๅ›ฝๅ†œไธš็ง‘ๅญฆ้™ข็”Ÿ็‰ฉๆŠ€ๆœฏ็ ”็ฉถๆ‰€ ็ผ–็ ็ฆฝๆตๆ„Ÿ่ก€ๅ‡็ด ็š„ๅŸบๅ› ๅŠๅ…ถๆค็‰ฉ่กจ่พพ่ฝฝไฝ“ๅ’Œๅบ”็”จ
CA2613160A1 (fr) * 2005-06-24 2006-12-28 Bayer Bioscience N.V. Methodes servant a modifier la reactivite de parois cellulaires de plantes
CN101227920A (zh) 2005-07-19 2008-07-23 ้™ถๆฐ็Žฏ็ƒๆŠ€ๆœฏๅ…ฌๅธ ้‡็ป„ๆตๆ„Ÿ็–ซ่‹—
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
ES2543056T3 (es) 2005-10-18 2015-08-14 Novavax, Inc. Partรญculas funcionales similares al virus de la gripe (VPL)
EP2360175B1 (fr) * 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Particules de type virus (vlps) de norovirus et de sapovirus
CA2642054C (fr) 2006-02-13 2017-11-21 Fraunhofer Usa, Inc. Antigenes de la grippe, compositions de vaccins et procedes associes
US7993655B2 (en) 2006-04-21 2011-08-09 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US8519113B2 (en) 2006-05-22 2013-08-27 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
US20070286873A1 (en) 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
EP2120762A1 (fr) 2007-01-17 2009-11-25 Lerner Medical Devices, Inc. Dispositif de photothรฉrapie ร  fibres optiques
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
NZ598417A (en) 2007-06-15 2013-06-28 Centre Nat Rech Scient Modifying glycoprotein production in plants
KR100964462B1 (ko) 2007-07-10 2010-06-16 ์„ฑ๊ท ๊ด€๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ํ˜•์งˆ์ „ํ™˜ ์‹๋ฌผ ์œ ๋ž˜์˜ ์กฐ๋ฅ˜๋…๊ฐ ๋ฐ”์ด๋Ÿฌ์Šค ๋ฐฑ์‹  ๋ฐ ๊ทธ ์ œ์กฐ๋ฐฉ๋ฒ•
CA2615372A1 (fr) 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
RU2358981C2 (ru) * 2007-08-07 2009-06-20 ะฆะตะฝั‚ั€ "ะ‘ะธะพะธะฝะถะตะฝะตั€ะธั" ะ ะพััะธะนัะบะพะน ะะบะฐะดะตะผะธะธ ะะฐัƒะบ ะฃะฝะธะฒะตั€ัะฐะปัŒะฝะฐั ะฒะฐะบั†ะธะฝะฐ ะฟั€ะพั‚ะธะฒ ะฒะธั€ัƒัะฐ ะณั€ะธะฟะฟะฐ ะฟั‚ะธั†
US20110059130A1 (en) 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
CN101422128B (zh) * 2007-10-29 2011-06-08 ไธญๅ›ฝๆฐดไบง็ง‘ๅญฆ็ ”็ฉถ้™ข้ป„ๆตทๆฐดไบง็ ”็ฉถๆ‰€ ้ฉฌๅฐพ่—ปๅŽŸ็”Ÿ่ดจไฝ“็š„ๅˆ†็ฆปๅ’Œๅ†็”Ÿ
EP2238253B1 (fr) 2007-11-27 2012-09-12 Medicago Inc. Particules pseudovirales (vlp) de la grippe recombinรฉes produites dans des plantes transgรฉniques exprimant l'hรฉmagglutinine
CN101909454A (zh) * 2007-12-28 2010-12-08 ่ทๅ…ฐ่”ๅˆๅˆฉๅŽๆœ‰้™ๅ…ฌๅธ ไปŽ่Œถๅ›žๆ”ถ้ฆ™ๅ‘ณๅŒ–ๅˆ็‰ฉ็š„ๆ–นๆณ•
US8799801B2 (en) 2008-01-16 2014-08-05 Qualcomm Incorporated Interactive ticker
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
EP2294202B1 (fr) 2008-07-08 2015-05-20 Medicago Inc. Antigรจnes de la grippe recombinรฉs solubles
CN101626276A (zh) 2008-07-10 2010-01-13 ๅŽไธบๆŠ€ๆœฏๆœ‰้™ๅ…ฌๅธ ๅนฟๅ‘Šๆ›ฟๆขๆ–นๆณ•ใ€่ฃ…็ฝฎๅŠ็ณป็ปŸ
SG192503A1 (en) 2008-07-18 2013-08-30 Medicago Inc New influenza virus immunizing epitope
JP5785080B2 (ja) 2008-08-27 2015-09-24 ใ‚ขใƒชใ‚พใƒŠใƒปใƒœใƒผใƒ‰ใƒปใ‚ชใƒ–ใƒปใƒชใƒผใ‚ธใ‚งใƒณใƒ„ใƒปใƒ•ใ‚ฉใƒผใƒปใ‚ขใƒณใƒ‰ใƒปใ‚ชใƒณใƒปใƒ“ใƒใƒผใƒ•ใƒปใ‚ชใƒ–ใƒปใ‚ขใƒชใ‚พใƒŠใƒปใ‚นใƒ†ใ‚คใƒˆใƒปใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ๏ผก๏ฝ’๏ฝ‰๏ฝš๏ฝ๏ฝŽ๏ฝ ๏ผข๏ฝ๏ฝ๏ฝ’๏ฝ„ ๏ผฏ๏ฝ† ๏ผฒ๏ฝ…๏ฝ‡๏ฝ…๏ฝŽ๏ฝ”๏ฝ“ ๏ผฆ๏ฝ๏ฝ’ ๏ผก๏ฝŽ๏ฝ„ ๏ผฏ๏ฝŽ ๏ผข๏ฝ…๏ฝˆ๏ฝ๏ฝŒ๏ฝ† ๏ผฏ๏ฝ† ๏ผก๏ฝ’๏ฝ‰๏ฝš๏ฝ๏ฝŽ๏ฝ ๏ผณ๏ฝ”๏ฝ๏ฝ”๏ฝ… ๏ผต๏ฝŽ๏ฝ‰๏ฝ–๏ฝ…๏ฝ’๏ฝ“๏ฝ‰๏ฝ”๏ฝ™ ๆค็‰ฉใซใŠใ‘ใ‚‹ใƒฏใ‚ฏใƒใƒณๅŠใณใƒขใƒŽใ‚ฏใƒญใƒผใƒŠใƒซๆŠ—ไฝ“ๆฒป็™‚่–ฌใฎ้ซ˜ใƒฌใƒ™ใƒซ่ฟ…้€Ÿ็”Ÿ็”ฃใฎใŸใ‚ใฎ๏ฝ„๏ฝŽ๏ฝใƒฌใƒ—ใƒชใ‚ณใƒณ็ณป
US20100167376A1 (en) * 2008-10-06 2010-07-01 Genvault Corporation Methods for providing cellular lysates from cell wall-containing samples
WO2010077712A1 (fr) 2008-12-09 2010-07-08 Novavax, Inc. Particule de type viral du virus syncytial respiratoire bovin (vlps)
MX2011007916A (es) 2009-01-30 2011-11-18 Adlyfe Inc Pรฉptidos conformacionalmente dinรกmicos.
EA201791744A3 (ru) 2009-06-10 2018-07-31 ะั€ะฑัƒั‚ัƒั ะ‘ะธะพั„ะฐั€ะผะฐ ะšะพั€ะฟะพั€ัะนัˆะฝ ะฃะปัƒั‡ัˆะตะฝะฝะฐั ะปะธะฟะธะดะฝะฐั ะบะพะผะฟะพะทะธั†ะธั
SI2440231T1 (sl) 2009-06-10 2020-08-31 Nono Inc. Soฤasno dajanje sredstva, vezanega na internalizacijski peptid tat, z inhibitorjem degranulacije mastocitov
IN2012DN00650A (fr) 2009-06-24 2015-06-12 Medicago Inc
NO2480658T3 (fr) 2009-09-22 2018-02-03
ES2614527T3 (es) 2010-11-04 2017-05-31 Medicago Inc. Sistema de expresiรณn en plantas
CN103282023B (zh) 2010-11-05 2018-09-21 ่ฏบ็“ฆ็“ฆๅ…‹ๆ–ฏ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็‹‚็Šฌ็—…็ณ–่›‹็™ฝ็—…ๆฏ’ๆ ท้ข—็ฒ’(vlp)
TWI526539B (zh) 2010-12-22 2016-03-21 ่‹œ่“ฟ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆค็‰ฉไธญ็”Ÿ็”ข้กž็—…ๆฏ’้ก†็ฒ’(vlp)็š„ๆ–นๆณ•ๅŠไปฅ่ฉฒๆ–นๆณ•็”Ÿ็”ขไน‹vlp
TWI620816B (zh) 2011-03-23 2018-04-11 ่‹œ่“ฟ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆค็‰ฉ่ก็”Ÿ่›‹็™ฝๅ›žๆ”ถๆ–นๆณ•

Also Published As

Publication number Publication date
IL257261A (en) 2018-03-29
WO2011035423A1 (fr) 2011-03-31
US20130067807A1 (en) 2013-03-21
CN107090021A (zh) 2017-08-25
PT2480560T (pt) 2018-04-03
BR112012006414B1 (pt) 2020-09-15
RU2579903C2 (ru) 2016-04-10
KR20120093223A (ko) 2012-08-22
EP2480658B1 (fr) 2017-09-06
JP2013505272A (ja) 2013-02-14
ZA201202835B (en) 2015-08-26
BR112012006414A2 (pt) 2016-11-16
KR20180026562A (ko) 2018-03-12
PL3354657T3 (pl) 2022-05-09
SI3354657T1 (sl) 2022-05-31
SG178918A1 (en) 2012-04-27
KR20190050862A (ko) 2019-05-13
DK2480658T3 (da) 2017-11-06
CN102549148A (zh) 2012-07-04
NO2480560T3 (fr) 2018-07-21
HUE036776T2 (hu) 2018-07-30
IL218393A0 (en) 2012-04-30
US11826419B2 (en) 2023-11-28
HUE058165T2 (hu) 2022-07-28
NZ598508A (en) 2014-02-28
HUE038557T2 (hu) 2018-10-29
DK2480560T3 (en) 2018-04-16
PT3354657T (pt) 2022-05-06
PL2480658T3 (pl) 2017-12-29
IL257261B (en) 2020-03-31
MX2012003373A (es) 2012-05-29
CN102549008A (zh) 2012-07-04
DK3354657T3 (da) 2022-04-19
EP2480658A1 (fr) 2012-08-01
AU2010300033B2 (en) 2015-01-22
NZ598481A (en) 2014-02-28
HRP20220478T1 (hr) 2022-05-27
BR112012006414A8 (pt) 2017-10-10
EP3354657B1 (fr) 2022-01-26
AU2010300033A1 (en) 2012-03-22
IL218422A0 (en) 2012-04-30
HRP20171564T1 (hr) 2017-11-17
CA2772962A1 (fr) 2011-03-31
JP2013505025A (ja) 2013-02-14
HRP20180509T1 (hr) 2018-05-04
US11833200B2 (en) 2023-12-05
RU2012115661A (ru) 2013-10-27
MY164704A (en) 2018-01-30
ES2911037T3 (es) 2022-05-17
CN107129973A (zh) 2017-09-05
NO2480658T3 (fr) 2018-02-03
AU2010300034A1 (en) 2012-03-22
JP5554414B2 (ja) 2014-07-23
ES2642631T3 (es) 2017-11-17
RU2567012C2 (ru) 2015-10-27
EP2480658A4 (fr) 2013-02-27
BR112012006415B1 (pt) 2020-04-28
PT2480658T (pt) 2017-11-13
IL218422B (en) 2018-03-29
AU2010300034B2 (en) 2015-07-30
KR20120072371A (ko) 2012-07-03
KR102115226B1 (ko) 2020-05-27
CA2772964A1 (fr) 2011-03-31
SG178947A1 (en) 2012-04-27
BR112012006415A2 (pt) 2016-11-16
MY158475A (en) 2016-10-14
AR078432A1 (es) 2011-11-09
EP3354657A1 (fr) 2018-08-01
EP2480560A1 (fr) 2012-08-01
EP2480560A4 (fr) 2013-01-23
MX2012003372A (es) 2012-05-29
AR078433A1 (es) 2011-11-09
IN2012DN02591A (fr) 2015-08-28
IL270661B (en) 2021-12-01
EP2480560B1 (fr) 2018-02-21
WO2011035422A1 (fr) 2011-03-31
IN2012DN02637A (fr) 2015-09-04
SI2480658T1 (sl) 2017-11-30
PL2480560T3 (pl) 2018-06-29
ES2662778T3 (es) 2018-04-09
US20120178149A1 (en) 2012-07-12
RU2012115996A (ru) 2013-10-27
JP5551780B2 (ja) 2014-07-16
KR101773431B1 (ko) 2017-09-12
TR201803560T4 (tr) 2019-01-21
CA2772962C (fr) 2013-04-02
ZA201202836B (en) 2012-12-27
SI2480560T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
CA2772964C (fr) Procede de preparation de proteines derivees de plantes
AU2017202473B2 (en) Method of recovering plant-derived proteins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150805